electroCore, Inc.（ECOR）股票分析ECORelectroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Currently, electroCore, Inc. (ECOR) is not a good buy. The stock is trading at $7.16, which is significantly below its 52-week high of $12.70, indicating a potential for further downside. Additionally, the RSI is at 33.004, suggesting that the stock is oversold, but this could also mean continued weakness in the short term. The forward P/E ratio is extremely high at 384.6154, reflecting investor skepticism about future earnings growth, while insider selling has increased by 666.36% over the last month, indicating a lack of confidence from those closest to the company. The main risk is the negative earnings trend, with an EPS estimate of -0.26 for the next earnings report, which could further pressure the stock price.

2 analysts cover ECOR: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 15.00.